A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine

被引:47
|
作者
Gallagher, RM
Dennish, G
Spierings, ELH
Chitra, R
机构
[1] Univ Med & Dent New Jersey, Headache Ctr, Moorestown, NJ 08057 USA
[2] Univ Calif San Diego, San Diego, CA 92103 USA
[3] San Diego Cardiovasc Associates, Damluji Res Ctr, San Diego, CA USA
[4] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Boston, MA 02115 USA
[6] Zeneca Pharmaceut, Wilmington, DE USA
来源
HEADACHE | 2000年 / 40卷 / 02期
关键词
headache; migraine; sumatriptan; zolmitriptan;
D O I
10.1046/j.1526-4610.2000.00017.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-This randomized, double-blind, parallel group multicenter study compared response rates and tolerability of zolmitriptan with sumatriptan in the acute treatment of migraine. Methods.-A sample consisting of 1445 outpatients with an established diagnosis of migraine was randomized to zolmitriptan, 2.5 mg or 5 mg, or sumatriptan, 25 mg or 50 mg. Patients took 1 tablet for moderate/severe migraine and a second identical tablet, if necessary, for recurrent headache of moderate/severe intensity 4 to 24 hours after the initial dose. Up to six attacks were treated during a 6-month period. The primary outcome measure was headache response 2 hours after the initial dose. Secondary end points included 1-hour and 4-hour headache response and pain relief over 24 hours. Results.-A headache response at 2 hours was noted in 67.1% of patients taking zolmitriptan, 2.5 mg, and 64.8% of those taking zolmitriptan, 5 mg, versus 59.6% of patients taking sumatriptan, 25 mg, and 63.8% of those taking sumatriptan, 50 mg. At 2 and 4 hours, the differences between zolmitriptan, 2.5 mg, and sumatriptan, 25 mg, were statistically significant (odds ratio=1.49 and 1.67, respectively; both P<.001). Statistically significant differences between zolmitriptan, 2.5 mg, and sumatriptan, 50 mg, were seen at 2 and 4 hours post dose (odds ratio=1.21 and 1.23, respectively; both P<.05). At 1 hour post dose, the headache response rate for zolmitriptan, 2.5 mg, was numerically higher than response rates for sumatriptan, 25 mg and 50mg (odds ratio=1.16, odds ratio=1.06, though they failed to reach statistical significance; P=.061, P=.461 respectively). Differences between zolmitriptan, 5 mg, and sumatriptan, 25 mg, were statistically significant at 1, 2, and 4 hours (odds ratio=1.43, 1.46, anal 1.78, respectively; all P<.001) and at 1 and 4 hours versus sumatriptan, 50 mg (odds ratio=1.28, P=.002; odds ratio=1.29, P=.012, respectively). Although not statistically significant at 2 hours, more patients responded to zolmitriptan, 5 mg, than to sumatriptan, 50 mg (odds ratio=1.16, P=.064). Patients receiving zolmitriptan, 2.5 mg or 5 mg, achieved more pain relief over 24 hours than patients receiving sumatriptan, 25 mg (odds ratio=1.47, and 1.54 respectively, both P<.001) or sumatriptan, 50 mg (odds ratio=1.17, P=.021; odds ratio=1.22, P=.005, respectively); All treatments were well tolerated. Conclusions.-Zolmitriptan, 2.5 mg and 5 mg, was at least as effective as sumatriptan, 25 mg or 50 mg, for all parameters studied. Zolmitriptan, 2.5 mg, was significantly more effective than sumatriptan, 50 mg, in terms of headache response at 2 and 4 hours. Patients taking zolmitriptan were significantly more likely to have pain relief over 24 hours than those taking sumatriptan.
引用
收藏
页码:119 / 128
页数:10
相关论文
共 50 条
  • [1] Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: A comparative open trial
    Mathew, NT
    Kailasam, J
    Gentry, P
    Chernyshev, O
    HEADACHE, 2000, 40 (06): : 464 - 465
  • [2] Comparison of zolmitriptan and sumatriptan for the acute treatment of migraine.
    Gallagher, RM
    CEPHALALGIA, 1999, 19 (04) : 358 - 358
  • [3] A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migrane (vol 40, pg 119, 2000)
    Gallagher, RM
    Dennish, G
    Spierings, ELH
    Chitra, R
    ARCHIVES DE PEDIATRIE, 2000, 7 (03): : 327 - 327
  • [4] Transcranial Doppler in migraine attacks before and after treatment with oral zolmitriptan or sumatriptan
    Thomaides, T
    Karagounakis, D
    Spantideas, A
    Katelanis, S
    HEADACHE, 2003, 43 (01): : 54 - 58
  • [5] Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study
    Gruffyd-Jones, K
    Kies, B
    Middleton, A
    Mulder, LJMM
    Rosjo, O
    Millson, DS
    EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (03) : 237 - 245
  • [6] Acute treatment of migraine with oral and subcutaneous sumatriptan
    Dahlof, CGH
    CEPHALALGIA, 1997, 17 (05) : 559 - 560
  • [7] Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine
    Tfelt-Hansen, P
    Teall, J
    Rodriguez, F
    Giacovazzo, M
    Paz, J
    Malbecq, W
    Block, GA
    Reines, SA
    Visser, WH
    HEADACHE, 1998, 38 (10): : 748 - 755
  • [8] Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine
    Steiner, TJ
    Diener, HC
    MacGregor, EA
    Schoenen, J
    Muirhead, N
    Sikes, CR
    CEPHALALGIA, 2003, 23 (10) : 942 - 952
  • [9] Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design
    Geraud, G
    Olesen, J
    Pfaffenrath, V
    Tfelt-Hansen, P
    Zupping, R
    Diener, HC
    Sweet, R
    CEPHALALGIA, 2000, 20 (01) : 30 - 38
  • [10] ORAL SUMATRIPTAN IN ACUTE MIGRAINE
    GOADSBY, PJ
    ZAGAMI, AS
    DONNAN, GA
    SYMINGTON, G
    ANTHONY, M
    BLADIN, PF
    LANCE, JW
    LANCET, 1991, 338 (8770): : 782 - 783